Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair
NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, effective May 15. She succeeds Alan Holmer, who will remain on the Board.
“We thank Alan for his over ten years of dedicated service as founding Chair of the Corbus Board,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. “Rachelle is a seasoned biopharmaceutical executive, and we have greatly benefitted from her innovative and strategic thinking as a Board member. We look forward to following her vision and continued leadership as we enter an exciting new chapter for Corbus, with clinical readouts from all three of the drugs in our pipeline expected in the 2nd half of this year”.
"It is a privilege to step into the Board Chair role at such a pivotal time for Corbus as we advance our diverse pipeline toward key milestones this year,” said Rachelle Jacques. “Our targeted oncology programs, CRB-701 and CRB-601, are designed to strike at the heart of aggressive cancers, while our obesity program has the potential to address one of the most urgent public health challenges of our time. The opportunity to drive meaningful change for patients is immense and deeply motivating."
“It has been an honor and privilege to serve as Chair of the Corbus Board”, said Alan Holmer. “We are clearly on a positive and exciting trajectory. Rachelle has been a highly valued member of the Board and brings deep and broad corporate experience in both big pharma and biotech. I look forward to working closely with her to ensure a smooth transition.”
Rachelle Jacques has served on the Corbus Pharmaceuticals Board of Directors for more than six years, contributing to the Audit, Compensation, and Governance and Nominating Committees. With more than 25 years of leadership experience across CEO, commercial, financial, and operational roles, she has a strong track record of success advancing and launching transformative therapies. Jacques also serves on the board of directors of uniQure N.V. (Nasdaq: QURE), a biotechnology company advancing gene therapies for patients with severe genetic diseases. She was previously CEO and a board member of Akari Therapeutics Plc (Nasdaq: AKTX), a late-stage biotechnology company developing treatments for autoimmune and inflammatory diseases. Before that, she served as CEO of Enzyvant Therapeutics, where she led the successful U.S. Food and Drug Administration approval of RETHYMIC®, one of the first three therapies authorized under the Regenerative Medicine Advanced Therapy (RMAT) designation.
Earlier in her career, Jacques held executive roles including senior vice president and global complement franchise head at Alexion Pharmaceuticals, where she led global commercialization strategy across hematology, nephrology, and neurology. She also served as vice president of U.S. hematology marketing at Baxalta, vice president of business operations at Baxalta following its spinoff from Baxter International, and held multiple leadership positions at Baxter, including vice president of finance for the U.S. BioScience business. At Dow Corning she held operational management roles across the United States, Europe, and China. Jacques earned a bachelor’s degree in business administration from Alma College, where she also serves on the board of trustees.
About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 receptor inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit . Connect with us on , and .
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s trial results, product development, clinical and regulatory timelines, including timing for completion of trials and presentation of data, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies.
INVESTOR CONTACT:
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
Bruce Mackle
Managing Director
LifeSci Advisors, LLC
